Holen Sie sich die Stockscreener-App
4.9645
6.19%
-0.3655
Schlusskurs vom Vortag:
$5.33
Offen:
$5.33
24-Stunden-Volumen:
19,123
Relative Volume:
0.08
Marktkapitalisierung:
$108.66M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.87M
KGV:
-1.5471
EPS:
-3.2089
Netto-Cashflow:
$-61.75M
1W Leistung:
-15.97%
1M Leistung:
-36.71%
6M Leistung:
-17.90%
1J Leistung:
-36.79%
1-Tages-Spanne:
$4.96
$5.456
1-Wochen-Bereich:
$4.98
$6.19
52-Wochen-Spanne:
$3.35
$17.94
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Firmenname
Aardvark Therapeutics Inc
Sektor
Branche
Telefon
(858) 225-7696
Adresse
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
4.965 | 116.65M | 0 | -69.87M | -61.75M | -3.2089 |
VRTX
Vertex Pharmaceuticals Inc
|
522.11 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.76 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.25 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.30 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.67 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2026-03-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2026-03-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-03-02 | Herabstufung | Stifel | Buy → Hold |
| 2026-01-28 | Eingeleitet | B. Riley Securities | Buy |
| 2025-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2025-12-12 | Eingeleitet | William Blair | Outperform |
| 2025-12-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-11-07 | Eingeleitet | BTIG Research | Buy |
| 2025-09-29 | Eingeleitet | Stifel | Buy |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-10 | Eingeleitet | BofA Securities | Buy |
| 2025-03-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-03-10 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aardvark Therapeutics Inc Aktie (AARD) Neueste Nachrichten
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. LawsuitAARD - PR Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARD - GlobeNewswire Inc.
Aardvark Therapeutics Lawsuit: Investors Can Lead Securities Fraud Case - WBOC TV
AARDVARK THERAPEUTICS, INC. (AARD) SHAREHOLDER ALERT - GlobeNewswire
Deadline Alert: Aardvark Therapeutics, Inc. (AARD) - GlobeNewswire
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline - PR Newswire
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - The Conway Daily Sun
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-09-06 | AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:AARD | Press Release - Stockhouse
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline - TMX Newsfile
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Eastern Progress
Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) S - The National Law Review
Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (NASDAQ: AARD) Investors to Seek Counsel Before October 13, 2026 Lead Plaintiff Deadline in the Securities Class Action - PR Newswire
DEADLINE ALERT for HDB, SMPL, and AARD: The Law Offices of - GlobeNewswire
AARD Shareholder Alert: October 13, 2026 Lead Plaintiff Deadline in Aardvark Therapeutics, Inc. Securities Class ActionContact SueWallSt - PR Newswire
AARD SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
AARD Investor Alert: Aardvark Therapeutics, Inc. Securities Class Action NoticeContact Levi & Korsinsky - morningstar.com
Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aardvark Therapeutics, Inc. Class Action Lawsuit Alert: - GlobeNewswire
Important Notice to Long-Term Shareholders of Aardvark - GlobeNewswire
AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark - GlobeNewswire
Important Notice to Long-Term Shareholders Aardvark - GlobeNewswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages Aardvark - GlobeNewswire
AARD STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (AARD) Investors - The National Law Review
Robbins LLP Urges AARD Stockholders Who Lost Money Investing in Aardvark Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action - PR Newswire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
AARD Shareholder Alert: Aardvark Therapeutics, Inc. Securities Class Action LawsuitInvestors Should Contact SueWallSt - Morningstar
AARD Investor Notice: Hagens Berman Alerts Investors in Aardvark Therapeutics (AARD) to Filing of Securities Class Action - TMX Newsfile
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
AARD DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Aardvark Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
Deadline Approaching: Aardvark Therapeutics, Inc. (AARD) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - The Chronicle-Journal
AARD DEADLINE: Levi & Korsinsky Reminds Aardvark Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Aardvark Therapeutics, Inc. Investors - GlobeNewswire
Oct. 31st DEADLINE ALERT: Investors Who Lost Money With Aardvark Therapeutics, Inc. (NASDAQ: AARD) Shares Should Contact the Shareholders Foundation in Connection With Lawsuit - Business Wire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Aardvark - GlobeNewswire
Did You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARD - newsfilecorp.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
AARD INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aardvark Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Aardvark Therapeutics, Inc. (AARD) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 13, 2026 - ACCESS Newswire
2026-08-21 | Faruqi & Faruqi, LLP Urges Aardvark Therapeutics (NASDAQ: AARD) Investors to Seek Counsel Before October 13, 2026 Lead Plaintiff Deadline in the Securities Class Action | NDAQ:AARD | Press Release - Stockhouse
Aardvark Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsAARD - WBOC TV
Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Sahm
Aardvark Therapeutics (AARD) gives director 10-year options at $6.54 - Stock Titan
Aardvark Therapeutics Lawsuit Alleges Investors Were Misled Before Sharp AARD Stock Drops - TipRanks
LAWSUIT ALERT: Investors who lost over $100,000 with Aardvark Therapeutics, Inc. (NASDAQ: AARD) between February 2025 and May 2026, should contact the Shareholders Foundation - Morningstar
AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program - Stocktwits
Finanzdaten der Aardvark Therapeutics Inc-Aktie (AARD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aardvark Therapeutics Inc-Aktie (AARD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lee Tien-Li | Chief Executive Officer |
Dec 11 '25 |
Buy |
14.48 |
7,000 |
101,395 |
1,551,613 |
| Lee Tien-Li | Chief Executive Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,229 |
5,211 |
1,544,613 |
| Jones Bryan | Chief Operating Officer |
Oct 15 '25 |
Option Exercise |
4.24 |
1,250 |
5,300 |
1,250 |
| Lee Tien-Li | Chief Executive Officer |
Sep 15 '25 |
Buy |
9.66 |
10,000 |
96,624 |
1,543,384 |
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):